Compare SHO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | HRMY |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | 36 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | SHO | HRMY |
|---|---|---|
| Price | $9.32 | $28.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $9.19 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $3.77 | $19.87 |
| Revenue Next Year | $3.58 | $12.49 |
| P/E Ratio | $966.33 | ★ $10.48 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $7.45 | $25.52 |
| 52 Week High | $10.23 | $40.87 |
| Indicator | SHO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 32.81 |
| Support Level | $8.61 | $27.66 |
| Resistance Level | $9.35 | $37.38 |
| Average True Range (ATR) | 0.29 | 1.66 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 38.27 | 27.06 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.